Semax is a synthetic heptapeptide derived from the ACTH(4–10) fragment, originally developed in Russia for neuroprotective and cognitive enhancement research. It was specifically engineered to retain the neurotrophic and nootropic effects of ACTH while eliminating the hormonal stimulation associated with cortisol release. Research interest in Semax centers on neuroplasticity, BDNF upregulation, cognitive performance, stroke recovery, neurotransmitter modulation, and neuronal protection.
Studies have demonstrated that Semax significantly increases expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), both of which play central roles in synaptic plasticity, memory formation, learning, and neuronal repair. Additional research suggests Semax modulates dopaminergic and serotonergic signaling pathways while reducing oxidative stress and inflammatory signaling within the central nervous system. These combined mechanisms have made Semax one of the most extensively studied nootropic peptides in modern peptide research.
Semax has been investigated in experimental models involving ischemic stroke, traumatic brain injury, cognitive decline, optic nerve damage, ADHD, and neurodegenerative disease. Russian clinical use and preclinical data have contributed to a substantial body of literature exploring its effects on mental clarity, focus, recovery, and neural resilience.
While Semax has a long history of medical use in Russia and Eastern Europe, it remains an investigational compound in most Western countries and is intended strictly for laboratory and scientific research purposes.
Citations:
https://pubmed.ncbi.nlm.nih.gov/11387277/
https://pubmed.ncbi.nlm.nih.gov/18097752/
https://pubmed.ncbi.nlm.nih.gov/25796615/
https://peptidescienceinstitute.org/peptide-library/semax/
https://peptide.co/research/semax-peptide-research/
https://www.peptidesinstitute.org/peptides/semax
